@article{3088367,
    title = "Topical treatment of basal cell carcinoma with the immune response modifier imiquimod",
    author = "Papakostas, D. and Stockfleth, E.",
    journal = "Future Oncology",
    year = "2015",
    volume = "11",
    number = "22",
    pages = "2985-2990",
    publisher = "Future Medicine Ltd",
    issn = "1479-6694, 1744-8301",
    doi = "10.2217/fon.15.192",
    keywords = "imiquimod;  aminoquinoline derivative;  antineoplastic agent;  imiquimod;  immunologic factor, Article;  basal cell carcinoma;  drug efficacy;  drug safety;  drug tolerability;  government regulation;  human;  immune response;  nonhuman;  pharmacodynamics;  postmarketing surveillance;  priority journal;  cancer staging;  Carcinoma, Basal Cell;  chemistry;  clinical trial (topic);  pathology;  Skin Neoplasms;  topical drug administration;  treatment outcome, Administration, Topical;  Aminoquinolines;  Antineoplastic Agents;  Carcinoma, Basal Cell;  Clinical Trials as Topic;  Humans;  Immunologic Factors;  Neoplasm Staging;  Product Surveillance, Postmarketing;  Skin Neoplasms;  Treatment Outcome",
    abstract = "Imiquimod, a TLR7 agonist, is a novel immune response modifier currently widely used in the treatment of actinic keratoses (in situ squamous cell carcinoma). Imiquimod has revolutionized the treatment of field cancerization and has been approved for the treatment of superficial basal cell carcinoma with the recommendation of a 6-week treatment strategy, offering an alternative to surgery or other destructive treatment strategies. © 2015 Future Medicine Ltd."
}